Chessells J M, Hardisty R M, Richards S
Br J Cancer. 1987 Mar;55(3):315-9. doi: 10.1038/bjc.1987.62.
Long term follow-up of 378 children with acute lymphoblastic leukaemia (ALL) treated at a single centre showed that at six years from diagnosis 202 (53%) were alive, of whom 140 (37%) remained in first remission. Only three children had a first relapse after six years. Children who survived six years despite a single extramedullary relapse in the testis or CNS were likely to remain in second remission but patients with previous marrow or with multiple relapses continued at risk for up to ten years from diagnosis. Presenting factors influencing event-free survival were: leucocyte count, age and sex. After allowing for these factors morphological (FAB) subtype and liver enlargement retained their prognostic significance. Immunological type of ALL was not of independent prognostic significance, except for the small number of patients with B-ALL. Most factors lost their significance after 2-4 years. It is concluded that patients alive 6 years from diagnosis without relapse or even with a single extramedullary relapse of ALL, have a high chance of prolonged survival and cure.
对在单一中心接受治疗的378例急性淋巴细胞白血病(ALL)患儿进行的长期随访显示,自确诊起6年时,202例(53%)存活,其中140例(37%)仍处于首次缓解期。只有3例患儿在6年后出现首次复发。尽管在睾丸或中枢神经系统出现单次髓外复发,但存活6年的患儿可能仍处于第二次缓解期,但既往有骨髓复发或多次复发的患者在确诊后长达10年仍有风险。影响无事件生存的呈现因素有:白细胞计数、年龄和性别。在考虑这些因素后,形态学(FAB)亚型和肝脏肿大仍保留其预后意义。ALL的免疫类型除少数B-ALL患者外,无独立的预后意义。大多数因素在2 - 4年后失去其意义。得出的结论是,自确诊起存活6年且无复发甚至有单次ALL髓外复发的患者,有很高的机会实现长期生存和治愈。